Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter a1

American Journal of Physiology - Cell Physiology

Volumn 301, Issue 3, 2011, Pages

  Liu, Donghui ^a   Ji, Liang ^a   Tong, Xunliang ^c   Pan, Bing ^a   Han, Jing Yan ^d   Huang, Yining ^c   Chen, Y Eugene ^e   Pennathur, Subramaniam ^e   Zhang, Youyi ^a,b   Zheng, Lemin ^a  

^a Peking University Health Science Center   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d PEKING UNIVERSITY   (China)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apolipoprotein a i; High density lipoprotein; Human umbilical vein endothelial cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CYCLOOXYGENASE 2; HIGH DENSITY LIPOPROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PERTUSSIS TOXIN; PROSTACYCLIN; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ARTICLE; ATHEROGENESIS; CELL ISOLATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG SYNERGISM; EPOPROSTENOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS, NONESTERIFIED; FLAVONOIDS; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; JANUS KINASE 2; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERTUSSIS TOXIN; PHOSPHOLIPIDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHINGOSINE; TRYPSIN; TYRPHOSTINS; UP-REGULATION;

EID: 80052252850     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00055.2011     Document Type: Article

References (49)

1. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol 22: 630-637, 2002.
2. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 48: 2325-2333, 2007.
3. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54: 321-341, 2003.
4. Bolli R, Dawn B, Xuan YT. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13: 72-79, 2003.
5. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23: 1724-1731, 2003.
6. Calleros L, Lasa M, Toro MJ, Chiloeches A. Low cell cholesterol levels increase NFkappaB activity through a p38 MAPK-dependent mechanism. Cell Signal 18: 2292-2301, 2006.
7. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, Oda MN. The interplay between size, morphology, stability, and functionality of highdensity lipoprotein subclasses. Biochemistry 47: 4770-4779, 2008.
8. Cham BE, Knowles BR. A solvent system for delipidation of plasma or serum without protein precipitation. J Lipid Res 17: 176-181, 1976.
9. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous den-sity gradient ultracentrifugation in a vertical rotor. J Lipid Res 21: 284-291, 1980.
10. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Highdensity lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15: 1987-1994, 1995.
11. Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-Selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 19: 910-917, 1999.
12. Damirin A, Tomura H, Komachi M, Tobo M, Sato K, Mogi C, Nochi H, Tamoto K, Okajima F. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 67: 1177-1185, 2005.
13. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 25: 1017-1058, 1984.
14. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257: 6653-6655, 1982.
15. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem 273: 21099-21104, 1998.
16. Gonzalez-Diez M, Rodriguez C, Badimon L, Martinez-Gonzalez J. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost 100: 119-126, 2008.
17. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15, 1989.
18. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15, 2006.
19. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, III, Roux-Lombard P, Burger D. Apolipoprotein A-I inhibits the production of interleukin-1_ and tumor necrosis factor-_ by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381-2389, 2001.
20. Keul P, Sattler K, Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev 12: 301-306, 2007.
21. Kim JI, Jo EJ, Lee HY, Cha MS, Min JK, Choi CH, Lee YM, Choi YA, Baek SH, Ryu SH, Lee KS, Kwak JY, Bae YS. Sphingosine 1-phosphate in amniotic fluid modulates cyclooxygenase-2 expression in human amnion-derived WISH cells. J Biol Chem 278: 31731-31736, 2003.
22. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276: 31780-31785, 2001.
23. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, Murakami M, Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 23: 1283-1288, 2003.
24. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82: 13Q-21Q, 1998.
25. LaPointe MC, Isenovic E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 33: 276-282, 1999.
26. Linton MF, Fazio S. Cyclooxygenase-2 atherosclerosis. Curr Opin Lipidol 13: 497-504, 2002.
27. Marin V, Kaplanski G, Gres S, Farnarier C, Bongrand P. Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells. J Immunol Methods 254: 183-190, 2001.
28. Mart'inez-González J, Escudero I, Badimon L. Simvastatin potenciates PGI2 release induced by HDL in human VSMC: effect on Cox-2 upregulation and MAPK signalling pathways activated by HDL. Atherosclerosis 174: 305-313, 2004.
29. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 98: 1352-1364, 2006.
30. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665, 1976.
31. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9: 693-700, 1968.
32. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113: 569-581, 2004.
33. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/ PGI-synthase coupling. Arterioscler Thromb Vasc Biol 24: 871-877, 2004.
34. Norata GD, Catapano AL. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag 1: 119-129, 2005.
35. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. N Engl J Med 352: 1081-1091, 2005.
36. O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. Circulation 104: 1978-1983, 2001.
37. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an antiatherogenic mediator? Biochim Biophys Acta 1582: 132-137, 2002.
38. Pomerantz KB, Fleisher LN, Tall AR, Cannon PJ. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J Lipid Res 26: 1269-1276, 1985.
39. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, Celermajer DS, Rye KA. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 196: 240-247, 2008.
40. Rauramaa R, Salonen JT, Kukkonen-Harjula K, Seppanen K, Seppala E, Vapaatalo H, Huttunen JK. Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid: a controlled randomised trial in middle aged men. Br Med J (Clin Res Ed) 288: 603-606, 1984.
41. Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 22: 983-988, 2002.
42. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 17: 2158-2166, 1997.
43. Symons JD. Longitudinal and cross-sectional studies of the relationship between 6-keto PGF1 alpha and high density lipoproteins. Prostaglandins Leukot Essent Fatty Acids 39: 159-165, 1990.
44. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 284: 32336-32343, 2009.
45. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 279: 7622-7628, 2004.
46. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423-433, 2011.
47. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, Levkau B, Zeiher AM, Dimmeler S, Haendeler J. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 27: 275-282, 2007.
48. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol Gastrointest Liver Physiol 270: G393-G400, 1996.
49. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7: 853-857, 2001.